Who
Ivan Hyep
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Bicara Therapeutics.
In numbers
- Trades disclosed
- 81
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $5.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Oct 2025
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K12,500 at $3.79 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $350K12,500 at $27.97 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K12,500 at $3.79 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $350K12,500 at $27.97 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K12,500 at $3.79 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $651K22,757 at $28.60 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $132K4,413 at $29.82 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,592 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —908 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $25K830 at $30.31 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,592 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —908 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K12,500 at $3.79 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $651K22,757 at $28.60 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $132K4,413 at $29.82 | filing |
| 8 Jul 2026filed 10 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $25K830 at $30.31 | filing |
| 21 May 2026filed 26 May 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $35K9,200 at $3.79 | filing |
| 21 May 2026filed 26 May 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $188K9,200 at $20.42 | filing |
News
No headline names them, or the companies they trade most, lately.